FLUPHENAZINE DECANOATE Drug Patent Profile
Which patents cover Fluphenazine Decanoate, and when can generic versions of Fluphenazine Decanoate launch?
Fluphenazine Decanoate is a drug marketed by Eugia Pharma, Fresenius Kabi Usa, Gland, Hikma, Hospira, MSN, Mylan Labs Ltd, Ph Health, and Teva Parenteral. and is included in nine NDAs.
The generic ingredient in FLUPHENAZINE DECANOATE is fluphenazine decanoate. There is one drug master file entry for this compound. Nine suppliers are listed for this compound. Additional details are available on the fluphenazine decanoate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Fluphenazine Decanoate
A generic version of FLUPHENAZINE DECANOATE was approved as fluphenazine decanoate by FRESENIUS KABI USA on July 14th, 1987.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for FLUPHENAZINE DECANOATE?
- What are the global sales for FLUPHENAZINE DECANOATE?
- What is Average Wholesale Price for FLUPHENAZINE DECANOATE?
Summary for FLUPHENAZINE DECANOATE
| US Patents: | 0 |
| Applicants: | 9 |
| NDAs: | 9 |
| Finished Product Suppliers / Packagers: | 9 |
| Raw Ingredient (Bulk) Api Vendors: | 1 |
| Clinical Trials: | 2 |
| Patent Applications: | 2,482 |
| Drug Prices: | Drug price information for FLUPHENAZINE DECANOATE |
| DailyMed Link: | FLUPHENAZINE DECANOATE at DailyMed |
Recent Clinical Trials for FLUPHENAZINE DECANOATE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Tufts Medical Center | Phase 2 |
| Immune Control | Phase 2 |
| National Institute of Mental Health (NIMH) | Phase 4 |
Pharmacology for FLUPHENAZINE DECANOATE
| Drug Class | Phenothiazine |
